Patents by Inventor Mark E. Gurney

Mark E. Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080146540
    Abstract: Methods for diagnosis of asthma or allergic rhinitis or a susceptibility to asthma or allergic rhinitis based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. Also methods for treatment of asthma or allergic rhinitis or a susceptibility to asthma or allergic rhinitis based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. In particular, pathways targeting for treating individuals who are at-risk of developing asmtha or allergic rhinitis are described. In certain aspects, MLK1 inhibitors are used in treatment methods.
    Type: Application
    Filed: July 26, 2007
    Publication date: June 19, 2008
    Inventors: Hakon Hakonarson, Mark E. Gurney, Eva Halapi
  • Patent number: 7378511
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: May 27, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 7375187
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: May 20, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowaki, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 7368536
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: May 6, 2008
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Publication number: 20080033013
    Abstract: Two chemical genera of pyrazolylphenyl and pyrrolylphenyl derivatives are disclosed. They have the general formula: In these compounds ring (a) is a pyrazole or pyrrole; Q is selected from the group consisting of a direct bond, O, S, SO, SO2, NR1, CH2, CF2, and C(O); HET is a 4-7-membered saturated nitrogenous heterocycle; and taken together ZW is H or Z is (CH2)1-10 in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; and W is hydrogen, acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl or substituted heterocyclyl. The compounds are inhibitors of LTA4H (leukotriene A4 hydrolase). They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 7, 2008
    Applicant: deCODE genetics ehf.
    Inventors: Vincent Sandanayaka, Jasbir Singh, Lei Zhao, Peng Yu, Mark E. Gurney
  • Patent number: 7309811
    Abstract: The invention provides transgenic animals that are heterozygous or homozygous for a nonfunctional allele of BACE-1. These animals show normal development indicating that BACE-1 is not necessary for development and hence is an appropriate therapeutic target. The transgenic animals are useful in various screening assays including identifying inhibitors of other enzymes involved in processing of APP to A? and determining a toxicity profile of inhibitors of BACE-1.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: December 18, 2007
    Assignees: Elan Pharmaceuticals, Inc, Pharmacia & Upjohn Company
    Inventors: Lisa McConlogue, Mark E. Gurney
  • Publication number: 20070149544
    Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
    Type: Application
    Filed: August 3, 2006
    Publication date: June 28, 2007
    Applicant: DECODE CHEMISTRY, INC.
    Inventors: Vincent SANDANAYAKA, Jasbir SINGH, Li-Ming ZHOU, Mark E. GURNEY
  • Publication number: 20070142434
    Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
    Type: Application
    Filed: August 3, 2006
    Publication date: June 21, 2007
    Applicant: DECODE CHEMISTRY, INC.
    Inventors: Vincent Sandanayaka, Jasbir Singh, Lei Zhao, Mark E. Gurney
  • Publication number: 20070142432
    Abstract: The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
    Type: Application
    Filed: August 3, 2006
    Publication date: June 21, 2007
    Applicant: deCODE Chemistry, Inc.
    Inventors: Vincent Sandanayaka, Jasbir Singh, Mahnaz Keyvan, Michael David Krohn, Mark E. Gurney
  • Patent number: 7205120
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a ?-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
  • Patent number: 7041473
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cell and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: May 9, 2006
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6913918
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: July 5, 2005
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6867018
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: March 15, 2005
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6835565
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: December 28, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael Jerome Bienkowski, Robert Leroy Heinrikson, Luis A. Parodi, Riqiang Yan
  • Publication number: 20040253706
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a &bgr;-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: March 16, 2004
    Publication date: December 16, 2004
    Applicant: Pharmacia & Upjohn Company, a Delaware corporation
    Inventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
  • Publication number: 20040254341
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a &bgr;-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: March 16, 2004
    Publication date: December 16, 2004
    Applicant: Pharmacia & Upjohn Company, a Delaware corporation
    Inventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
  • Publication number: 20040254342
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a &bgr;-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: March 16, 2004
    Publication date: December 16, 2004
    Applicant: Pharmacia & Upjohn Company, a Delaware corporation
    Inventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
  • Patent number: 6828117
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: December 7, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Publication number: 20040241792
    Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a &bgr;-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
    Type: Application
    Filed: March 16, 2004
    Publication date: December 2, 2004
    Applicant: Pharmacia & Upjohn Company, a Delaware corporation
    Inventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
  • Patent number: 6825023
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: November 30, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan